Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00019604 · ClinicalTrials.gov registry record · Phase 2
Radiofrequency Ablation in Treating Patients With Unresectable Primary or Metastatic Liver Cancer
A Phase 2 study, sponsored by National Institutes of Health Clinical Center (CC).
- Terminated
- Registry status
- Phase 2
- Development phase
- 44
- Enrollment target
NCT00019604 is a Phase 2 study that was terminated before completion, run by National Institutes of Health Clinical Center (CC). The registered enrollment target is 44 participants.
The verdict
NCT00019604, a Phase 2 study, was terminated before completion, sponsored by National Institutes of Health Clinical Center (CC).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 44 participants
- Enrollment target
Study Summary
RATIONALE: Radiofrequency ablation is a procedure that heats tumors to several degrees above body temperature and may kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of radiofrequency ablation in treating patients who have unresectable primary or metastatic liver cancer.
Interventions
- PROCEDURE positron emission tomography
- PROCEDURE computed tomography
- PROCEDURE radionuclide imaging
- PROCEDURE magnetic resonance imaging
- PROCEDURE radiofrequency ablation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 1998-08 |
| Est. Completion | 2009-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00019604
The ClinicalTrials.gov registry entry for NCT00019604 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institutes of Health Clinical Center (CC), which has 338 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which positron emission tomography is the first listed.
NCT00019604 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00019604 about?
NCT00019604 is a clinical study titled "Radiofrequency Ablation in Treating Patients With Unresectable Primary or Metastatic Liver Cancer". RATIONALE: Radiofrequency ablation is a procedure that heats tumors to several degrees above body temperature and may kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of radiofrequency ablation in treating patients who have unresectable primary or metastatic liver cancer.
What is the current status of trial NCT00019604?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 1998-08. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00019604?
The interventions under investigation include: positron emission tomography (PROCEDURE), computed tomography (PROCEDURE), radionuclide imaging (PROCEDURE), magnetic resonance imaging (PROCEDURE), radiofrequency ablation (PROCEDURE).
Who is sponsoring clinical trial NCT00019604?
This trial is sponsored by National Institutes of Health Clinical Center (CC), which has 338 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.